Genmab stock reflects higher 2026 revenue guidance

Published on 09/29/2026 at 10:25 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Genmab stock trades at DKK 2,282.00 on September 28, 2026, after a 0.22 percent rise. H1 revenue reached USD 2.051 billion, up 25 percent year over year.

Fotorealistisches Biotech-Labor mit Forschern in weißen Kitteln bei Antikörperforschung — Genmab A/S entwickelt Antikörpertherapien in modernen Biotech-Laboren mit Forschern und Präzisionsgeräten, Aktie DK0010272202, Illustration mit AI erstellt.

Genmab (ISIN DK0010272202) stock was last at DKK 2,282.00 on Nasdaq Copenhagen on September 28, 2026, up DKK 5.00 or 0.22 percent. The biotechnology company is carrying higher 2026 revenue guidance and a stronger first-half top line into the final quarter.

Guidance reaches USD 4.525 billion

According to MetaTrader in its Genmab interim report for the six months ended June 30, 2026, revenue reached USD 2.051 billion, compared with USD 1.640 billion a year earlier. That represents 25 percent growth, while adjusted operating profit rose to USD 656 million from USD 554 million.

The same report lists revised full-year 2026 revenue guidance of USD 4.325 billion to USD 4.525 billion, versus the previous USD 4.065 billion to USD 4.395 billion range. Adjusted operating profit guidance stands at USD 1.065 billion to USD 1.385 billion, giving the stock a concrete earnings framework beyond the daily quotation.

Profit rises while debt changes

Genmab's six-month operating profit was USD 555 million, compared with USD 548 million in the prior-year period, while net profit fell to USD 356 million from USD 531 million. The contrast matters because the Merus acquisition added USD 5.135 billion of total borrowings, against zero in the comparable period, according to MetaTrader.

That balance-sheet change creates a sharper distinction between operating performance and bottom-line earnings. Cash and cash equivalents totaled USD 1.503 billion at June 30, 2026, while operating cash flow was USD 54 million for the first half.

Analysts set targets above ADR quote

MarketBeat reported that Guggenheim raised its Genmab target from USD 40.00 to USD 42.00 in a report dated August 7, 2026. The overview also lists H.C. Wainwright's Buy rating and USD 40.00 target from September 14, 2026, while the consensus target is USD 39.50.

For investors, the key tension is visible in the numbers: revenue growth accelerated, but net profit declined as acquisition financing increased interest costs. Genmab's pipeline and royalty income therefore remain important, while debt servicing adds a measurable counterweight to the higher guidance.

Stock holds near yearly high

Genmab stock was last at DKK 2,282.00 on September 28, 2026, within the DKK 1,512.00 to DKK 2,334.00 52-week range. The session high was DKK 2,315.00, the low was DKK 2,278.00 and volume was 19,650 shares on Nasdaq Copenhagen.